Executive Summary
THE PROVIDENCIA GROUP LLC secured a $270M obligation federal contract (potential $485M with options) for HHS refugee sponsor services, with $216M already outlayed, signaling robust revenue visibility through 2026-2027. This single large award dominates the period's professional services stream, highlighting concentration risk in minority-owned consulting firms. Investors should prioritize monitoring option exercises and funding draws amid labor-hour pricing vulnerabilities.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Federal Professional Services Contracts digest from March 20, 2026.
Investment Signals (1)
- $270M Obligation with $216M Outlayed (HIGH)▲
Significant revenue stream for Providencia Group from DOI contract supporting HHS ORR, with base + options reaching $485M.
Risk Flags (1)
- Execution [HIGH RISK]▼
Only $216M of $270M obligation outlayed over long period to 2026-2027, plus labor hours pricing audit exposure.
Opportunities (1)
- ◆
Potential $214M upside from exercising all options to $485M total, plus possible 1-year extension.
Sector Themes (1)
- ◆
Single $270M award underscores heavy federal reliance on minority-owned firms for NAICS 541611 services tied to HHS ORR.
Watch List (1)
- 👁
{"entity"=>"THE PROVIDENCIA GROUP LLC", "reason"=>"Dominates period with $270M obligation and expansion potential to $485M.", "trigger"=>"Option exercises exceeding $214M or outlays surpassing 80% of obligation"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Federal Professional Services Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals